Roche and Genentech opened a 1 million-square-foot Innovation Center in Allston on Thursday, establishing a new hub for cardiovascular, renal and metabolism (CVRM) research. The center, backed by a 10-year lease, will employ up to 500 people across research, clinical development, and data science, with artificial intelligence specialists embedded alongside discovery teams.
The facility is part of a joint $50 billion investment by the Switzerland-based Roche and its subsidiary Genentech in U.S. manufacturing and R&D. Other locations in the plan include sites in North Carolina and Oregon. The Allston center sits within the mixed-use Harvard Enterprise Research Center, which is still under development.
"This investment in Boston is an important part of our commitment to expand our U.S. manufacturing and R&D footprint," said Roche Group CEO Thomas Schinecker. "By investing in scientific talent, new capabilities and infrastructure, we are strengthening our ability to discover and develop the next generation of medicines for patients."
AI and data science in drug development
The companies said the center will house "AI specialists" working directly with discovery and clinical researchers. Roche pointed to existing related work that includes using AI in cancer research to identify targeted treatment approaches and analyze the effectiveness of new cancer drugs in clinical trials. The company has also worked on combating antibiotic-resistant bacteria.
For research scientists moving into roles that blend domain expertise with computational methods, structured AI Learning Path for Research Scientists resources can bridge the gap between traditional lab skills and the data-driven techniques now embedded in drug discovery pipelines. The center's design - placing AI specialists alongside bench researchers - reflects a broader industry shift toward integrated teams rather than siloed computational groups.
Boston's life sciences cluster expands
The Allston opening adds to a dense corridor of research activity in the Boston area. Gov. Maura Healey framed the decision as a validation of the region's workforce and institutions. "Roche and Genentech's decision to expand their presence here is another powerful vote of confidence in Massachusetts and in the people who make our state a global center for discovery and innovation," Healey said.
Boston Mayor Michelle Wu said the center "will create hundreds of jobs, drive new investment and further strengthen Boston's life sciences ecosystem." The facility's end-to-end R&D scope - spanning early discovery through clinical development - means it will house a wider range of scientific roles than a single-function research outpost.
Why this matters for science and research professionals
The Roche Genentech center signals sustained demand for researchers who can operate at the intersection of wet-lab science and computational methods. Job listings that once asked for either biology expertise or programming skills increasingly require both. For scientists planning their next career move, the 500 positions in Allston represent a concrete example of how large pharma employers are structuring their R&D teams - with AI for Science & Research capabilities treated as core to the work, not a separate support function.
Your membership also unlocks:
